In a Swiss study published by Welti et al in Oncotarget, among 350 patients diagnosed with metastatic melanoma, those who developed a COVID-19 infection (n = 25) usually had a mild case, with systemic therapy being administered throughout the disease course to the patients. Patients who had more severe COVID-19 infection were more likely to be older and have more comorbidities than patients who had a milder infection. The researchers concluded that continuing systemic therapy/immunotherapy after a risk assessment—despite infection with the virus—should be the goal whenever possible.
May 24, 2023